300 related articles for article (PubMed ID: 20139363)
1. Inhibition of factor XIa as a new approach to anticoagulation.
Schumacher WA; Luettgen JM; Quan ML; Seiffert DA
Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):388-92. PubMed ID: 20139363
[TBL] [Abstract][Full Text] [Related]
2. Coagulation factor XI as a novel target for antithrombotic treatment.
Löwenberg EC; Meijers JC; Monia BP; Levi M
J Thromb Haemost; 2010 Nov; 8(11):2349-57. PubMed ID: 20727068
[TBL] [Abstract][Full Text] [Related]
3. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice.
Wang X; Smith PL; Hsu MY; Gailani D; Schumacher WA; Ogletree ML; Seiffert DA
J Thromb Haemost; 2006 Sep; 4(9):1982-8. PubMed ID: 16961605
[TBL] [Abstract][Full Text] [Related]
4. Factor XI: hemostasis, thrombosis, and antithrombosis.
He R; Chen D; He S
Thromb Res; 2012 May; 129(5):541-50. PubMed ID: 22197449
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic pathway of coagulation and arterial thrombosis.
Gailani D; Renné T
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2507-13. PubMed ID: 17916770
[TBL] [Abstract][Full Text] [Related]
6. Factor XI as a Therapeutic Target.
Gailani D; Gruber A
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1316-22. PubMed ID: 27174099
[TBL] [Abstract][Full Text] [Related]
7. Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week.
Harrington J; Piccini JP; Alexander JH; Granger CB; Patel MR
J Am Coll Cardiol; 2023 Feb; 81(8):771-779. PubMed ID: 36813377
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats.
Schumacher WA; Seiler SE; Steinbacher TE; Stewart AB; Bostwick JS; Hartl KS; Liu EC; Ogletree ML
Eur J Pharmacol; 2007 Sep; 570(1-3):167-74. PubMed ID: 17597608
[TBL] [Abstract][Full Text] [Related]
10. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
11. The intrinsic pathway of coagulation: a target for treating thromboembolic disease?
Gailani D; Renné T
J Thromb Haemost; 2007 Jun; 5(6):1106-12. PubMed ID: 17388803
[TBL] [Abstract][Full Text] [Related]
12. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
13. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery.
Yamashita A; Nishihira K; Kitazawa T; Yoshihashi K; Soeda T; Esaki K; Imamura T; Hattori K; Asada Y
J Thromb Haemost; 2006 Jul; 4(7):1496-501. PubMed ID: 16839345
[TBL] [Abstract][Full Text] [Related]
14. Factor XIa-specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis.
David T; Kim YC; Ely LK; Rondon I; Gao H; O'Brien P; Bolt MW; Coyle AJ; Garcia JL; Flounders EA; Mikita T; Coughlin SR
Sci Transl Med; 2016 Aug; 8(353):353ra112. PubMed ID: 27559095
[TBL] [Abstract][Full Text] [Related]
15. Targeting factor XI and factor XIa to prevent thrombosis.
Gailani D; Gruber A
Blood; 2024 Apr; 143(15):1465-1475. PubMed ID: 38142404
[TBL] [Abstract][Full Text] [Related]
16. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.
Lorentz CU; Verbout NG; Wallisch M; Hagen MW; Shatzel JJ; Olson SR; Puy C; Hinds MT; McCarty OJT; Gailani D; Gruber A; Tucker EI
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):799-809. PubMed ID: 30700130
[TBL] [Abstract][Full Text] [Related]
17. Factor XI and contact activation as targets for antithrombotic therapy.
Gailani D; Bane CE; Gruber A
J Thromb Haemost; 2015 Aug; 13(8):1383-95. PubMed ID: 25976012
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the discovery and development of factor XI/XIa inhibitors.
Al-Horani RA; Afosah DK
Med Res Rev; 2018 Sep; 38(6):1974-2023. PubMed ID: 29727017
[TBL] [Abstract][Full Text] [Related]
19. Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis.
Visser M; Heitmeier S; Ten Cate H; Spronk HMH
Thromb Haemost; 2020 Jun; 120(6):883-993. PubMed ID: 32375196
[TBL] [Abstract][Full Text] [Related]
20. Factor XI deficiency in animal models.
Renné T; Oschatz C; Seifert S; Müller F; Antovic J; Karlman M; Benz PM
J Thromb Haemost; 2009 Jul; 7 Suppl 1():79-83. PubMed ID: 19630774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
